Prognostic Value of ctDNA in Resected RCC: Current Evidence and Clinical Limits
Abstract
ctDNA is a promising prognostic biomarker in renal cell carcinoma, but further research is required before routine clinical use. Ongoing advances in tumor-informed assays and integrated biomarker strategies may soon yield precise, biology-driven postoperative risk stratification.
Fields of Study & Subjects
Renal cell carcinoma treatment
Cancer Genomics and Diagnostics
Radiomics and Machine Learning in Medical Imaging
Publication details
- Journal / source
- Default Digital Object Group
- Publication date
- 4 March 2026
- Language
- EN
- Document type
- Dataset